Prognostic significance of metabolic tumor volume measured by 18F-FDG PET/CT in operable primary breast cancer

Nuclear Medicine and Molecular Imaging

Volumn 46, Issue 4, 2012, Pages 278-285

  Kim, Jahae ^a   Yoo, Su Woong ^a   Kang, Sae Ryung ^a   Cho, Sang Geon ^a   Oh, Jong Ryool ^a   Chong, Ari ^a   Min, Jung Joon ^a   Bom, Hee Seung ^a   Yoon, Jung Han ^a   Song, Ho Chun ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Breast cancer; FDG PET CT; Maximum standardized uptake value; Metabolic tumor volume; prognosis

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; AGED; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING EQUIPMENT; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; METABOLIC TUMOR VOLUME; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY SCANNER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; RECURRENT CANCER; REVIEW; SENTINEL LYMPH NODE BIOPSY; STANDARDIZED UPTAKE VALUE; TUMOR VOLUME;

EID: 84875449966     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-012-0161-9     Document Type: Review

References (24)

1. Yoo K, Shin H, Park S, Yoon H, Shin A, Kang D, et al. Is Breast Cancer Incidence Rate Further Increasing in Korea? Korean J Epidemiol. 2001;23(2):1-7.
2. Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol. 2004;27(3):304-6.
3. Uematsu T, Kasami M, Yuen S. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy. Breast Cancer. 2009;16 (2):97-104.
4. 18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol. 2008;19(9):1573-7.
5. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging. 2008;35(3):475-83.
6. Song B-I, Hong CM, Lee HJ, Kang S, Jeong SY, Kim HW, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45(2):117-24.
7. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2011. doi:10.1245/s10434-011-2153-x.
8. Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012. doi:10.1007/s00259-011- 2059-7.
9. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDGPET/ CT in patients with cervical cancer. Gynecol Oncol. 2011;120 (2):270-4.
10. 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volume-based metabolic parameters. Head Neck. 2012; doi:10.1002/hed.22904.
11. Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012;19(1):69-77.
12. 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38(9):1628-35.
13. Kim K, Kim SJ, Kim IJ, Seong Kim Y, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012. doi:10.1097/MNM.0b013e328351d4f5.
14. Kim BS, Sung SH. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 2012;26(2):175-83.
15. Sanli Y, Kuyumcu S, Ozkan ZG, Isik G, Karanlik H, Guzelbey B et al. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med. 2012;26(4):345-50.
16. 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426-35.
17. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J NuclMed. 2010;51(4):543-50.
18. 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48(8):1266-72.
19. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15(6):588-93.
20. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317-23.
21. 18F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130(5):273-8.
22. Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol. 2010;28(17):2868-73.
23. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17(8):2334-40.
24. Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, et al. Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg. 2006;141(8):783-8.